Cyclophosphamide Monohydrate — Drug Intelligence | 37 EU Trials

Filter these 37 trials by condition, phase, country and more.

Open in Search →

37 Registered trials

17 Recruiting

16 Completed trials

32 Sponsors

22 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 10 Phase II: 14 Phase I/II: 5 Phase IV: 1 Phase I (FiH): 7

Oversight events:

35 temporary halts 3 urgent safety measures 4 unexpected events 4 corrective measures across 7 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 2 High-grade B-cell lymphoma 1 Peripheral T-cell lymphoma unspecified 1 Triple negative breast cancer 1 Acute lymphocytic leukaemia 1 Epstein-Barr virus associated lymphoma 1 Follicular lymphoma 1 Ovarian epithelial cancer 1 Systemic lupus erythematosus 1 Neuroblastoma 1 Pseudomyxoma peritonei 1 Chronic lymphocytic leukaemia 1

Sponsors using this IMP

Cabaletta Bio Inc. 2 Celgene Corp. 2 F. Hoffmann-La Roche AG 2 Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau 2 Iovance Biotherapeutics Inc. 2 Istituto Europeo Di Oncologia S.r.l. 2 Novartis Pharma AG 2 Amsterdam UMC 1 Ascentage Pharma Group Inc. 1 Autolus Limited 1 CanCell Therapeutics 1 Cellectis 1

All trials — page 2

37 total

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended

2022-501346-30-00 Phase III 12 countries Celgene Corp.
Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, … Ended

2024-518658-18-00 Phase II 1 country Medical University Of Warsaw
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult … Ended

2024-512903-38-00 Phase I/II 1 country Autolus Limited
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended

2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Ended

2023-507062-34-00 Phase I (FiH) 5 countries Novartis Pharma AG
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended

2024-511781-37-00 Phase II 3 countries Ceska Myelomova Skupina z.s.; Emn Trial Office S.r.l. Impresa Sociale; European …
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide mai… Ended

2024-516061-36-00 Phase II 1 country Hellenic Society Of Hematology
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended

2024-511975-14-00 Phase I/II 5 countries Pfizer Inc.
Study of combination of metronomic chemotherapy and reactivator of immune response in inflammatory breast cancer spread to the chest wall. Ended

2023-507365-26-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri… Ended

2023-504036-17-00 Phase III 3 countries F. Hoffmann-La Roche AG
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Phase III 2 countries NSABP Foundation Inc.
HD21 Ended

2024-518022-33-00 Phase III 6 countries University Of Cologne
PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phas… Ended

2024-514979-17-04 Phase II 1 country I.F.O. Istituti Fisioterapici Ospitalieri

Showing 25–37 of 37 trials

← All drugs A–Z